
Boin Hearing Technology (Shanghai)
AI intelligent hearing aids and hearing expert centres.
Date | Investors | Amount | Round |
---|---|---|---|
investor investor | €0.0 | round | |
investor investor | €0.0 | round | |
* | CNY20.0m Valuation: CNY500m | Series B | |
Total Funding | 000k |
Related Content
Boin Hearing Technology (Shanghai) Co., Ltd. is a national high-tech enterprise established in 2019, specializing in the hearing health sector. The company, founded by Chairman Jiang Xianquan, focuses on the integrated development, production, and sales of AI-enhanced hearing aids combined with a network of "hearing expert centers".
The company's operational history began with the establishment of a national operation center in Shanghai in June 2019. A significant step was taken in August 2020 with the formation of a Shanghai-based R&D center to focus on proprietary hearing aid technology. By January 2021, Boin Hearing had set up a production base in Minhang, Shanghai. A key milestone was achieved in August 2023, when the company secured both the Medical Device Registration Certificate and the Medical Device Production License from Chinese authorities, enabling it to commercialize its own products.
Boin Hearing's business model combines direct-to-consumer sales with a professional service infrastructure, aiming to provide a domestic alternative in the hearing aid market. The company generates revenue through the sale of its medical-grade hearing aid products. Its product portfolio includes its own branded series such as "Tang," "QIN," and "HAN," as well as bone conduction hearing aids. The company also distributes products from international brands like Beltone and Audio Service and collaborates on batteries with VARTA.
Financially, Boin Hearing has successfully moved through several funding stages. After an initial angel round in December 2020, it secured a Pre-A round in November 2022 from Su Gaoxin Venture Capital. A substantial Series A round of nearly CNY 100 million from Junlian Capital and Mingxi Capital followed in August 2023. The company has continued its funding trajectory with a Series B round, securing a total of $13.7M over four rounds as of mid-2025. These funds are allocated towards core R&D, supply chain enhancement, and market expansion.
Keywords: hearing aids, medical devices, HealthTech, AI hearing technology, audiology, hearing loss solutions, therapeutic devices, Chinese domestic market, venture capital-backed, medical-grade devices, hearing expert centers, wearables, assistive technology, sound amplification, audiology services, hearing care, hearing solutions, China healthcare, rehabilitative technology, MedTech